Interplay of platelet polymorphisms, risk factors and Von Willebrand factor, and flow-mediated conditions in determining collagen-adenosine diphosphate PFA-100 results in patients with coronary artery disease

Blood Coagulation and Fibrinolysis

Volumn 16, Issue 2, 2005, Pages 97-104

  Porto, Italo ^a   Leone, Antonio Maria ^b   Nanni, Luisa ^b   Sciahbasi, Alessandro ^b   De Vita, Maria ^b   Lanza, Gaetano Antonio ^b   Andreotti, Felicita ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Coronary artery disease; Genetic polymorphisms; Platelet function analyzer (PFA 100); Platelet reactivity

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RISTOCETIN; THIENO[2,3 B]PYRIDINE DERIVATIVE; THROMBOCYTE ANTIGEN; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; AGED; ANALYZER; ARTICLE; BIOCHEMISTRY; BLOOD FLOW; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; EX VIVO STUDY; FEMALE; GENDER; GENE; GENETIC POLYMORPHISM; GENOTYPE; HEREDITY; HPA 1 GENE; HPA 2 GENE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; SHEAR RATE; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOGENESIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 15744384807     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000161562.28646.94     Document Type: Article

References (38)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the coronary syndromes. N Engl J Med 1992; 326:310-318.
2. Trip MD, Cats VM, van Capelle FJ, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322:1549-1554.
3. Roth GJ. Developing relationships: arterial platelet adhesion, glycoprotein Ib, and leucine-rich glycoproteins. Blood 1991; 77:5-19.
4. Ruggeri ZM. Structure and function of von Willebrand factor. Thromb Haemost 1999; 82:576-584.
5. Ruggeri ZM. Role of von Willebrand factor in platelet thrombus formation. Ann Med 2000; 32(suppl 1):2-9.
6. Goto S, Sakai H, Goto M, Ono M, Ikeda Y, Handa S, Ruggeri Z. Enhanced shear-induced platelet aggregation in acute myocardial infarction. Circulation 1999; 99:608-613.
7. Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004; 110:1392-1397.
8. Lanza GA, Sestito A, Iacovella S, Morlacchi L, Romagnoli E, Schiavoni G, et al. Relation between platelet response to exercise and coronary angiographic findings in patients with effort angina. Circulation 2003; 107:1378-1382.
9. Ruggeri ZM. Perspective series: cell adhesion in vascular biology. J Clin Invest 1997; 99:559-564.
10. Furihata K, Nugent DJ, Kunicki TJ. Influence of platelet collagen receptor polymorphisms on risk for arterial thrombosis. Arch Pathol Lab Med 2002; 126:305-309.
11. Feng D, Lindpainter K, Larson MG, Rao VS, O'Donnell CJ, Lipinska I, et al. Increased platelet aggregability associated with platelet GpIIIa PIA2 polymorphisms: the Framingham Offspring study. Arterioscler Thromb Vasc Biol 1999; 19:1142-1147.
12. Lasne D, Krenn M, Pingault V, Arnaud E, Fiessinger JN, Aiach M, et al. Interdonor variability of platelet response to thrombin receptor activation: influence of PIA2 polymorphism. Br J Haematol 1997; 99:801-807.
13. Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, et al. Platelet GP IIIa PI(A) polymorphisms display different sensitivities to agonists. Circulation 2000; 101:1013-1018.
14. Goodall AH, Curzen N, Panesar M, Hurd C, Knight CJ, Ouwehand WH, Fox KM. Increased binding of fibrinogen to glycoprotein IIIa-proline 33 (HPA-1b, PIA2 Zwb) positive platelets in patients with cardiovascular disease. Eur Heart J 1999; 20:742-744.
15. Bennett JS, Catella-Lawson F, Rut AR, Vilaire G, Qi W, Kapoor SC, et al. Effect of the PIA2 alloantigen on the function of beta3 integrins in platelets. Blood 2001; 97:3093-3099.
16. Meiklejohn DJ, Urbaniak SJ, Greaves M. Platelet glycoprotein IIIa polymorphism HPA1b (PIA2): no association with platelet fibrinogen binding. Br J Haematol 1999; 105:664-666.
17. Cooke GE, Bray PF, Hamlington JD, Pham DM, Goldschmidt-Clermont PJ. PIA2 polymorphism and efficacy of aspirin [Letter]. Lancet 1998; 351:1253.
18. 3 integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001; 104:2666-2672.
19. 3 subunit. Br J Haematol 2000; 110:911-918.
20. Mazzucato M, Pradella P, de Angelis V, Steffan A, de Marco L. Frequency and functional relevance of genetic threonine 145/methionine 145 dimorphism in platelet glycoprotein Ib alpha in an Italian population. Transfusion 1996; 36:891-894.
21. Li CQ, Garner SF, Davies J, Smethurst PA, Wardell MR, Ouwehand WH. Threonine-145/methionine-145 variants of baculovirus produced recombinant ligand binding domain of GPIb alpha express HPA-2 epitopes and show equal binding of von Willebrand factor. Blood 2000; 95:205-211.
22. Cadroy Y, Sakariassen KS, Charlet JP, Thalamas C, Boneu B, Sie P. Role of 4 platelet membrane glycoprotein polymorphisms on experimental arterial thrombus formation in men. Blood 2001; 98:3159-3161.
23. Favaloro EJ. Clinical application of the PFA-100. Curr Opin Hematol 2002; 9:407-415.
24. Sestito A, Sciahbasi A, Landolfi R, Maseri A, Lanza GA, Andreotti F. A simple assay for platelet-mediated hemostasis in flowing whole blood (PFA-100): reproducibility and effects of sex and age. Cardiologia 1999; 44:661-665.
25. Hurd CM, Cavanagh G, Schuh A, Ouwehand WH, Metcalfe P. Genotyping for platelet specific antigens: techniques for the detection of single nucleotide polymorphisms. Vox Sang 2002; 83:1-12.
26. Bock M, De Haan J, Beck KH, Gutensohn K, Hertfelder HJ, Karger R, et al. Standardization of the PFA-100(R) platelet function test in 105 mmol/l buffered citrate: effect of gender, smoking, and oral contraceptives. Br J Haematol 1999; 106:898-904.
27. Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004; 35:175-178.
28. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88:230-235.
29. Pedreno J, Hurt-Camejo E, Wiklund O, Badimon L, Masana L. Platelet function in patients with familial hypertriglyceridemia: evidence that platelet reactivity is modulated by apo E content of very-low-density lipoprotein particles. Metabolism 2000; 49:942-949.
30. Held C, Hjemdahl P, Rehnqvist N, Wallen NH, Forslund L, Bjorkander I, et al. Haemostatic markers, inflammatory parameters and lipids in male and female patients in the Angina Prognosis Study in Stockholm (APSIS). A comparison with healthy controls. J Intern Med 1997; 241: 59-69.
31. Rydzewski A, Urano T, Nagai N, Takada Y, Katoh-Oishi Y, Taminato T, et al. Diurnal variation in serum remnant-like lipoproteins, platelet aggregation and fibrinolysis in healthy volunteers. Haemostasis 1997; 27: 305-314.
32. Otto C, Baumann M, Screiner T, Bartsch G, Borberg H, Schwandt P, Schmid-Schonbein H. Standardized ultrasound as a new method to induce platelet aggregation: evaluation, influence of lipoproteins and of glycoprotein IIb/IIIa antagonist tirofiban. Eur J Ultrasound 2001; 14: 157-166.
33. Kunes J, Devynck MA, Zicha J. Chronic changes in plasma triglyceride levels do modify platelet membrane microviscosity in rats. Life Sci 2000; 67:959-967.
34. Macchi L, Christiaens L, Brabant S, Sorel N, Ragot S, Allal J, et al. Resistance in vitro to low-dose aspirin is associated with platelet PIA1 (GP IIIa) polymorphism but not with C807T (GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol 2003; 42:1115-1119.
35. Simsek S, Bleeker PM, van der Schoot CE, von dem Borne AE. Association of a variable number of tandem repeats (VNTR) in glycoprotein Ib alpha and HPA-2 alloantigens. Thromb Haemost 1994; 72: 757-761.
36. Pontiggia L, Lassila R, Pederiva S, Schmid HR, Burger M, Beer JH. Increased platelet-collagen interaction associated with double homozygosity for receptor polymorphisms of platelet GPIa and GPIIIa. Arterioscler Thromb Vasc Biol 2002; 22:2093-2098.
37. Ulrichts H, Vanhoorelbeke K, Cauwenberghs S, Vauterin S, Kroll H, Santoso S, Deckmyn H. Von Willebrand factor but not α-thrombin binding to platelet glycoprotein Ib is influenced by the HPA-2 polymorphism. Arterioscler Thromb Vasc Biol 2003; 23:1302-1307.
38. Boncler MA, Golanski J, Paczuski R, Watala C. Polymorphisms of glycoprotein Ib affect the inhibition by aurintricarboxylic acid of the von Willebrand factor dependent platelet aggregation. J Mol Med 2002; 80:796-801.